Stock CZO CEAPRO INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Other languages Ceapro Inc Toronto S.E.

Equities

CZO

CA1499071076

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Aeterna Zentaris Inc. completed the acquisition of Ceapro Inc. in a merger of equals transaction.
Ceapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna Merger
Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co
Ceapro Inc. Announces Dosing of First Patients In Phase 1-2a Study of Avenanthramides
Ceapro Inc. Announces Commencement of Patient Dosing in its Phase 1-2a Study Evaluating its Product, Avenanthramides, for Potential Applications in Managing Conditions Related to Inflammation
Ceapro Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Ceapro Inc. Initiates Phase 1-2a Study Assessing Avenanthramides For Potential Applications in Inflammation Based Diseases
Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases
Ceapro Inc. Announces the Signing of A Technical Collaboration with NATEX Prozesstechnologie Gmbh to Accelerate the Scale-Up of Its Proprietary PGX Technology Towards Commercial Level
Ceapro Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Ceapro Extends International Supply and Distribution Agreement with German Provider of Active Ingredients, Symrise
Ceapro Inc. Extends Exclusive International Supply and Distribution Agreement with Symrise
Ceapro Inc. Announces Next Phase of Research Collaboration with the Angiogenesis Foundation
Ceapro Inc. Announces Resignation of Glenn Rourke as A Director
Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CZO Stock
  4. CZO Stock
  5. News Ceapro Inc
  6. Other languages